Recent Updates
Recently added Catalysts
VRCA Positive Sentiment Score: 70/100

Verrica Pharmaceuticals Announces Presentation at the Jefferies Healthcare Conference in New York

Key Takeaway: Verrica Pharmaceuticals Inc. has announced that its President and CEO, Ted White, will present at the Jefferies Healthcare Conference in New York from June 7-9, 2023. The event aims to discuss the company's developments in dermatological therapeutics, including its late-stage product candidates. Interested participants can access a live webcast of the event as well as a replay afterward, ensuring that stakeholders remain informed about the company's progress.

Market Sentiment Analysis

POSITIVE FACTORS

  • Verrica's CEO will present at a significant healthcare conference.
  • The company is actively developing solutions for major dermatological conditions.
  • The webcast provides accessible information for investors and stakeholders.

Full Press Release Details

WEST CHESTER, Pa., May 31, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President & Chief Executive Officer, will present at the upcoming Jefferies Healthcare Conference, which is being held at the New York Marriot Marquis from June 7-9, 2023.
Date: Thursday, June 8, 2023
Location: New York Marriot Marquis, 1535 Broadway, New York, NY 10036
Participants may access a live webcast of the event through the following link: https://wsw.com/webcast/jeff281/vrca/1847560
The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. The webcast replay will be available 30 days after the conclusion of live event, and the webcast replay expires on September 15, 2023.
About Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s late-stage product candidate, VP-102, is in development to treat molluscum, common warts and external genital warts, three of the largest unmet needs in medical dermatology. Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. The Company has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP- 315 (formerly LTX-315 and VP-LTX-315) for dermatologic oncology conditions. For more information, visit www.verrica.com.
FOR MORE INFORMATION, PLEASE CONTACT:
Chief Financial Officer

Frequently Asked Questions

When will Ted White present at the Jefferies Healthcare Conference?

Ted White will present on June 8, 2023, at the Jefferies Healthcare Conference.

Where is the Jefferies Healthcare Conference being held?

The conference is at the New York Marriot Marquis, located at 1535 Broadway, NY.

How can I access the live webcast of the presentation?

The live webcast can be accessed via a link on Verrica's website and directly at the event.

What is VP-102 developed by Verrica Pharmaceuticals?

VP-102 is a late-stage product candidate for treating molluscum, common warts, and external genital warts.

What is VP-103's purpose in Verrica's development pipeline?

VP-103 is being developed for the treatment of plantar warts.

Last updated: May 31, 2023